Back to News
Market Impact: 0.3
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
A $15.0 million award will support advancement of RECLAIM-LN, a Phase 2 potentially registrational trial of FT819, an off-the-shelf CAR T-cell therapy for lupus nephritis. The funding strengthens development resources for a late-stage clinical program targeting a serious autoimmune kidney disease.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Anthropic Goes Big on Compute, Microsoft Rethinks AI
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Details on U.S.-China trade negotiations coming Monday, USTR Greer says
- Meta's 'powerful breakout' sets up a unique trading strategy, says Mike Khouw
- At Meta Connect, the company’s smart glasses were everywhere
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More
- AI Tools for Family Offices: A Stack by Decision Type